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Objective: Determine Th lymphocytes concentration in patients with knee or hip osteoarthritis (OA).
Evaluate their change after HA viscosupplementation.
Methods: Patients with early primary knee or hip OA (ACR Criteria) were recruited in two groups: group
A was only observed longitudinally, group B was treated with a course of three weekly intra-articular
injections of HA. A healthy control group gender and age matched was enrolled too. All subjects were
followed for 3 months. Flow cytometry was performed from blood samples to assess T cells sub-
populations (CD3, CD4, CD8, CCR6, CD38, CxCR3, HLA DR) at baseline and at 3-months visit.
Results: 86 patients were recruited with OA: 49 in Group A (35 knee OA, 14 hip OA), 37 in Group B (24
knee OA, 13 hip OA). 23 in Control Group. Activated CD4 T cells (CD4þCD38þDRþ, CD4þCD38DRþ), Th2
(CD4þCXCR3CCR6),Th1 (CD4þCXCR3þCCR6) were higher at baseline in group A and B than in control
group. After the HA course activated T cells were lower in group B than in group A (P ¼ 0.01). Th17
(CD4þCXCR3CCR6þ) at baseline were higher in groups A and B than in control group and decreased
levels in Group B after the HA course were observed (P ¼ 0.03).
Conclusion: The presence of activated T cells in patients with OA conﬁrm that OA is a disease with an
immunological/inﬂammatory involvement. Our preliminary results seems to show that HA injections
could lower the levels of activated T cells, and so regulate the articular milieu.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a chronic, degenerative joint disease
characterized by the progressive destruction of articular cartilage,
joint space narrowing, subchondral bone remodeling, joint mar-
ginal osteophyte formation and synovitis. OA causes joint pain,
stiffness, swelling and reduced range-of-motion having a serious
impact on health related quality-of-life, showing several charac-
teristics with rheumatoid arthritis, including joint destruction and
synovitis.
OA can be diagnosed by the presence of joint irregularities and
deformities on X-radiographic images. The grade of jointA. Lùrati, Rheumatology Unit
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ternational. Published by Elsevier Ldegeneration reﬂects disease severity. Non-invasive biochemical
analyses have been developed to evaluate disease progress and
severity, and provide a nonradiographical alternative for the early
detection of OA. Many factors contribute to an increase risk of OA
and include obesity, genetics, aging, and trauma to the joint.
Although the etiology and pathophysiology of OA are both
poorly understood, it is believed that secreted inﬂammatory mol-
ecules (such as proinﬂammatory cytokines and adipokines) are
among the critical mediators of the disturbed processes implicated
in OA pathophysiology. Humoral and cellular immunity, both
innate and adaptive immune response, are known to be involved1.
In particular, in many studies on OA, it has been demonstrated that
an inﬂammatory synovium/synovitis has linked to increased
cartilage damage and pain2,3. Synovial tissue of OA patients show
inﬁltrates of immune cells including T-cells, B-cells and macro-
phages. Immunoglobulins and immune complexes against cartilage
components are detected in cartilage, synovium and plasma in OA
patients4,5. Finally, key role of complement activation in OA syno-
vium has been identiﬁed6.
From data literature, CD4þ T lymphocytes (particularly Th17
subtype) and their cytokines have been reported to play a majortd. All rights reserved.
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arthritis or OA. In a proinﬂammatory milieu, chondrocytes become
metabolically active and initiate inﬂammatory processes that
degrade articular cartilage and subchondral bone. Chondrocytes
secrete several inﬂammatory cytokines that work synergistically to
stimulate synthesis of enzymes that break down cartilage. Nor-
mally, synovial ﬂuid contains high levels of hyaluronic acid (HA, a
polysaccharide produced by the chondrocytes and synoviocytes)
that help to maintain high ﬂuid viscosity and the normal integrity
of the joint by attenuating inﬂammation and preserving the normal
cartilaginous matrix. In OA, the synovial ﬂuid viscosity and elas-
ticity are decreased. While HA may help to lubricate and cushion
the joint, it can help maintain cartilage matrix and minimize
inﬂammation. In OA, the molecular weight and concentration of HA
are reduced, thereby lowering ﬂuid viscosity and elasticity. Pro-
tection against articular injury is compromised and OA damage
ensues. Intra-articular injections of HA (i.e., viscosupplementation)
are approved worldwide for the treatment of pain associated with
OA of the knee. In addition to a purely mechanical effect due to the
viscosity of the products, intra-articular HA viscosupplementation
is thought to provide a range of biological actions including anti-
inﬂammatory effect. In vitro data suggest that supplemental HA
can suppress IL-1 production, and may increase synovial ﬂuid vis-
cosity7. We hypothesize that intra-articular HA can suppress not
only the local intra-articular proinﬂammatory milieu, but also can
reduce the overall inﬂammatory cytokine response. Primary pur-
pose of this study was to evaluate the circulating levels of activated
CD4þ and CD8þ lymphocytes in patients with OA, comparing with
healthy control. Secondary purpose was to evaluate the changes in
lymphocytes after 3 months from an intra-articular HA injection
course and the effectiveness in terms of variation of Lequesne Pain-
functional index.
Methods
Patients
Patients with hip or knee OA were recruited from the Rheu-
matology Unit Fornaroli Hospital from January 2012 to October
2013. The inclusion criteria were a diagnosis of bilateral knee or hip
OA according to ACR Criteria, with a the KellgreneLawrence score
of 2e3 and Pain VAS at least 50 mm on a 0e100 mm visual scale.
The exclusion criteria were: presence of rheumatoid arthritis or
other rheumatic diseases, pregnancy, allergic to hyaluronans,
currently experiencing a knee infection or skin infection around the
injection site. An age, sex and BMI matched control group was
screened for OA and, after exclusion of OA diagnosis, they were
recruited too between blood donors of our Hospital; this group
didn't meet hip or/and knee OA ACR criteria. Patients with diffuse
OA to many joints (e.g., OA of knee associated with hands OA or
wright OA or spine OA) were excluded. Weight bearing ante-
roposterior knee and hip anterior-posterior radiographs were
classiﬁed according to the KellgreneLawrence (KL) radiographic
rating scale. All patients, inclused controls, read, understood and
signed an informed consent and compiled a pain-functional
Lequesne Index. The trial was conducted in accordance with the
ethics principles of the Declaration of Helsinki andwas approved by
the local research ethics committees.
Analgesics, non-steroidal anti-inﬂammatory drugs (NSAIDs),
symptomatic slow acting drugs for OA (SYSADOAs) or disease
modifying (DMOADs) if taken before entering the trial were not
modiﬁed throughout the period of the study. Patients with OA
longitudinally evaluated were enrolled in Group A (group A1 with
35 knee OA and group A2 with 14 hip OA) and no intra-articular
treatment was performed in these groups. Patients with knee OA orhip OA treated with an HA intra-articular course were recruited in
Group B (B1: 24 knee OA and B2: 13 hip OA). 23 subjects were
enrolled ﬁnally as control-healthy group.
Knee intra-articular injection procedure
The patient sat with the extended knee(s). An anteromedial or
lateral approach was performed for these injections. A 20 g needle
was used and a syringe of 2 ml of viscosupplement was then
delivered. We used for viscosupplementation sodium hyaluronate
with a molecular weight of 800e1200 kDa (Sinovial Forte® 1.6%
2 ml IBSA). Two more injections were provided to each patient at
weekly intervals for a total of three injections.
Hip eco guided intra-articular injection procedure
Patients were examined supine, with the hip internally rotated
by 15e20. A 10 MHz linear transducer had a sterile device for bi-
opsy attached. Ultrasound scans of the hip joint were taken on an
anterior parasagittal axis, lateral to the femoral vessels. The probe
was aligned along the long axis of the femur neck to visualize both
the acetabulum and the femoral head. Using an anterosuperior
approach, a G20 (9 cm) spinal needle was inserted through the
biopsy guide into the joint capsule, until the femoral head was
reached. Using real time imaging software, the needle was inserted
until it was visualized in the articular recess and so HAwas injected.
A course of three injections with Sinovial Forte®was performed for
all patients with hip OA in the group B2.
Flow cytometry
Freshly drawn EDTA blood samples were analyzed by 8-color
ﬂow cytometry (FACSCanto II, Becton Dickinson, Milan) with the
following conjugated antibody panel: CD45-FITC; CXCR3-PE;
CD4-PerCP-Cy5.5; CCR6-PE-Cy7; CD38-Alexa 647; CD8-APC-H7;
CD3-V450; HLADR-V500 at the appropriate concentrations (all
from Becton Dickinson). After 20-min staining in the dark, 2 ml of
ammonium chloride lysing was added for 10 min. After centrifu-
gation at 1500 rpm for 7 min, the pellet was resuspended in 200 mL
of cold PBS and immediately analyzed.
At least 50,000 lymphocytes (deﬁned as CD45þþþ, SSClow cells)
were acquired.
The gating strategy included the parallel capture of CD4þ/CD3þ
and CD8þ/CD3þ cells in two separate downstream hierarchies. Each
parent subset was then further dissected into functional sub-
populations, namely CD4þ T cells as Th1 cells (CD4þ CXCR3þ
CCR6), Th2 cells (CD4þ CXCR3 CCR6) and Th17 cells (CD4þ
CXCR3 CCR6þ), respectively according to Maecker et al., 20128.
Both CD4þ and CD8þ cells were divided into quiescent
(CD38 HLADR) or activated elements (CD38þ and/or HLADRþ).
Functional subset percentages were calculated over the total
lymphocyte population and over the parent CD4þ or CD8þ subsets,
respectively, and all values were also recorded as absolute levels
per microliter on the basis of total lymphocyte count (Beckman
Coulter DXH800, Milan).
Statistical analysis
All the variables collected were normally distributed as stated
by ShapiroeWilk test. Homoscedasticity of variances was assessed
with Cochran/Hartley or Levene tests. Continuous variables were
presented as mean SD, and compared using two-tailed Student's
t-test or one-way analysis of variance (ANOVA). Links between
continuous variables collected in the groups during the study
period were estimated with MANOVA for repeated measures
Table I
Demographic data of whole population
Knee OA HIP OA Controls P
Total patients 35 not treated
pts (Group A1)
24 treated
pts (Group B1)
14 not treated
pts (Group A2)
13 treated pts
(Group B2)
23 pts
Age (±SD) 65.5 ± 1.2 years old 70 ± 4.8 years old 66 ± 0.8 years old 0.2
Sex (female) 30 pts (61.2%) 18 pts (66.6%) 15 pts (65.2%) 0.3
Median
BMI (±SD)
25.31 (±4.14) 26.50 (±3.14) 27 (±4.04) 0.1
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using nonparametric Spearman correlation coefﬁcients. Statistical
analyses were performed with SPSS version 15.0 (SPSS Inc., Chi-
cago, USA) for Windows. P-values <0.05 were considered statisti-
cally signiﬁcant.
Results
The study recruited 76 patients with OA randomly: 49 patients
were recruited in Group A (group A1with 21 knee OA and group A2
with 28 hip OA) and only observed longitudinally. 37 patients were
recruited in Group B (B1 24 with knee OA and B2 13 with hip OA)
and treated weekly with three intra-articular injection of HA.
Finally 23 age, sex and BMImatched healthy subjects were enrolled
in Control Group. There were no statistically signiﬁcant differences
in age, sex and BMI between patients and controls (Table I de-
mographic table).
Data at baseline
There wasn't any signiﬁcant difference between group A1 e A2
(OA observed patients) and group B1 and B2 (OA treated patients) in
pain-functional Lequesne index (P ¼ 0.062), although we observed
slightly higher values in the B1 and B2 groups. The mean percent-
ages of cells stained positive for CD4þ (total CD4þ lymphocytes),
CD4þCXCR3þCCR6 (Th1 cells), Th2 (CD4þCXCR3CCR6), CD4þ
CD38þ, CD4þ HLA-DRþ, CD4þ CD38þ HLA-DRþ (subtypes of acti-
vated CD4þ lymphocytes) were different among the ﬁve groups
(Table II and Figs. 1 and 2).
Interestingly, while the patients were randomly assigned to
Groups A or B, we observed marginally higher values of Th1, Th2
cells, Th 17 and activated T cells in group B1 and B2 towards group
A1 and A2 (P ¼ 0.067) with a weak relationship with Lequesne
index (Spearman Rho 0.34, P ¼ 0.07). This bias can be due to small
size of the groups.
Data at 3 months
Between baseline and the 3 months, in Group B1 and B2 there
was a signiﬁcant decrease of pain-functional Lequesne from 14.7Table II
T cells levels at baseline in the ﬁve groups
Control Group A1 Gro
CD4þ 454 ± 123 760 ± 254 87
Th1 164 ± 61 224 ± 71 22
Th2 93 ± 19 363 ± 138 41
Th17 50 ± 26 88 ± 86 7
CD4þDRþ 13 ± 4 18 ± 11 2
CD4þCD38þ 85 ± 32 193 ± 63 33
CD4þCD38 þ DRþ 6 ± 3 5 ± 2 7.(±2.02) to 9 (±1.02) points with a mean variation of 5.7 ± 2.4 points
(P ¼ 0.02).
Healthy control didn't’ show a signiﬁcant difference for cells
subtype between baseline and the 3 months, indicating the
absence of spontaneous variation over time (P ¼ 0.19). A non
signiﬁcant tendency for an increase of activated cells count was
observed in Group A1 and A2 (P ¼ 0.067 and P ¼ 0.072 respec-
tively). In Group B1 and B2 there was a signiﬁcant decrease of
CD4þ cells, Th1, Th2, Th 17 and all subtypes of activated T cells
(P ¼ 0.01) (Fig. 3) and this decrease correlated directly with the
pain-functional Lequesne Index (Spearman Rho ¼ 0.56, P ¼ 0.01).
The ANOVA analysis conﬁrmed the independent inﬂuence of
activated T cells and Th17 levels on Lequesne value with a signif-
icant Eta squared value of 15.6 ± 2.3 and 11.5 ± 1.6 respectively
(P ¼ 0.01) [Fig. 4(a) and (b)].
Discussion
Our data suggest a biological effect of HA and support a structure-
modifying role regulating the systemic pro inﬂammatory milieu. It's
well known that innate and adaptive immune responses are
involved in OA pathogenesis9. Monocytes/macrophages are among
the most abundant cell types present in the cellular inﬁltrates found
in the inﬂames synovium in OA4,10,11. Macrophage-derived cyto-
kines, including IL-1b and TNF-a are the major players in the carti-
lage breakdown in OA. They up-regulate the expression of MMP
family of catabolic enzymes, MMP-1, -3 and -1312e14 and stimulate
the production of ADAMTS-4 and -5 (aggrecanases) in human
chondrocytes15 and in human OA synovial ﬁbroblasts16. They also
suppress the anabolic mechanism in the cartilage tissue by inhibit-
ing the expression of type II collagen17,18 and proteoglycans19,20 in
chondrocytes, the two major components of the cartilage extra-
cellular matrix (ECM) in the cartilage.
Mononuclear cell inﬁltrates in synovial tissues have been re-
ported in OA21e23 and have been shown to contain primarily CD3þ
T cells24. The Th1 subset of T cells was found to be about 5 times
more than Th2 cells24 and higher levels of Th1 cytokines, IL-2 and
IFNg, were detected in most of OA patients25. T cells inﬁltrating the
synovial membrane express early (CD69), intermediate (CD25 and
CD38) and late (CD45RO) activation markers26.
Saito et al. reported a CD4þ/CD8þ ratio in OA ST (synovial tis-
sues) of 5:1 compared to normal ST, where the ratio is 2:127. Steiner
et al. found that the CD4þ/CD8þ ratio in OA was comparable to RA
(Rheumatoid Arthritis)28. Several population of T helper (Th) cells
can be distinguished in CD4 cells: Th1, Th2, Th17 as well as regu-
latory cells (Th3 and Tr1) with unique function and unique cytokine
patterns29e32. In particular, it has been showed that OA synovial
tissue is characterized by activated CD4þ T cells and by expression
of activation antigens (CD69, CD25, CD38, CD45RO, HLA Class II,
CD80, CD83)29. In OA synovial tissue the ratio CD4þ/CD8þ is 5:1 and
it is higher than in normal ST29 and it's comparable to RA ST. Also,
number of CD4þ T cells is higher in early OA compared to late OA
stage29.up A2 Group B1 Group B2 P Value
7 ± 79 976 ± 267 1227 ± 381 0.01
6 ± 18 273 ± 135 268 ± 118 0.03
2 ± 62 367 ± 148 321 ± 263 0.01
2 ± 8 88 ± 31 85 ± 61 0.01
0 ± 2.8 33 ± 32 34 ± 8 0.01
7 ± 45.2 363 ± 40 662 ± 203 0.03
1 ± 0.9 13 ± 10 16 ± 3 0.02
Fig. 1. Global Th CD4þ levels observed in each subject in the ﬁve groups at baseline
(*P ¼ 0.01 between mean values of control group and other OA groups).
Fig. 2. Activated Th cells CD4þCD38þ (continuous line) and CD4þDRþ (dotted line)
levels in the ﬁve groups at baseline (*P ¼ 0.01 between the CD4þCD38þ levels of
control group and OA groups; **P ¼ 0.04 between the CD4þDRþ levels of control group
and OA groups). Log10 scale used.
Fig. 3. Variation of Activated Th Cells CD4þCD38þ (black line) and CD4þDRþ (grey line)
after the course of HA. Cumulative data of groups B1 and B2. Log 10 scale used
(*P ¼ 0.01 between the CD4þCD38þ levels; **P ¼ 0.03 between the CD4þDRþ levels).
Fig. 4. a and b: Relationship between Lequesne functional pain value and activated Th
cells value at baseline and 3-months (linear regression model with observed Lequesne
pain value in Y axis and predicted adjusted value in X axis). Eta squared value between
activated Th cells and Lequesne index of 15.6 ± 2.3 and 11.5 ± 1.6 at baseline and at 3
months, respectively (P ¼ 0.02).
A. Lùrati et al. / Osteoarthritis and Cartilage 23 (2015) 88e93 91To our knowledge, this study is the ﬁrst one speciﬁcally
designed to measure the variations over time of OA T cells pheno-
type after HA injections.
The current study conﬁrm that Th1, Th2 cells and activated
T cells detectable in blood samples from patients with knee or hip
OA have increased levels compared with healthy subjects. Ac-
cording to data literature, our study found a signiﬁcant difference in
Th17 cells expression between OA and healthy subjects.
Furthermore, we have demonstrated that HA intra-articular
injections may reduce the count of activated T cells, mainly CD38þ
and DR þ cells, and Th 17 cells.
These data suggest an anti-inﬂammatory effect of HA. In sum-
mary, this exploratory study suggests that HA IA injections may
modify the knee or hip joint metabolism in patients with OA
resulting in a decrease in proinﬂammatory Tcells concentrations. In
particular it can reduce synovial inﬂammation and restore the
rheological properties of synovial ﬂuid. Further large scale pro-
spective placebo-controlled studies, coupling biomarkers and
A. Lùrati et al. / Osteoarthritis and Cartilage 23 (2015) 88e9392imaging techniques are needed to conﬁrm these results and to
investigate the possible disease modifying effect of HA as suggested
in this work.Declaration of contributions
Alfredomaria Lùrati MD PhD Conception and design Analysis
and interpretation of the data.
Antonella Laria MD Collection and assembly of data.
Daniela Mazzocchi MD Drafting of the article.
Re Katia Angela MD Collection and assembly of data.
Mariagrazia Marrazza MD Collection and assembly of data.
Magda Scarpellini MD Final approval of the article.Conﬂicts of interest
Authors have no ﬁnancial or personal relationships with people or
organizations that could potentially and inappropriately inﬂuence
the present study.References
1. Tsuruha J, Masuko-Hongo K, Kato T, Sakata M, Nakamura H,
Sekine T, et al. Autoimmunity against YKL-39, a human carti-
lage derived protein, in patients with osteoarthritis.
J Rheumatol 2002 Jul;29(7):1459e66.
2. Ayral X, Pickering EH, Woodworth TG, Mackillop N,
Dougados M. Synovitis: a potential predictive factor of struc-
tural progression of medial tibiofemoral knee osteo-
arthritisdresults of a 1 year longitudinal arthroscopic study in
422 patients. Osteoarthritis Cartilage 2005;13:361e7.
3. Hill CL, Hunter DJ, Niu J, Clancy M, Guermazi A, Genant H, et al.
Synovitis detected on magnetic resonance imaging and its
relation to pain and cartilage loss in knee osteoarthritis. Ann
Rheum Dis 2007;66:1599e603.
4. Revell PA1, Mayston V, Lalor P, Mapp P. The synovial mem-
brane in osteoarthritis: a histological study including the
characterisation of the cellular inﬁltrate present in inﬂamma-
tory osteoarthritis using monoclonal antibodies. Ann Rheum
Dis 1988;47:300e7.
5. Jasin HE. Immune mediated cartilage destruction. Scand
J Rheumatol Suppl 1988;76:111e6.
6. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ,
Larsen DM, et al. Identiﬁcation of a central role for comple-
ment in osteoarthritis. Nat Med 2011;17:1674e9.
7. Zhou PH, Liu SQ, Peng H. The effect of hyaluronic acid on
IL-1beta-induced chondrocyte apoptosis in a rat model of
osteoarthritis. J Orthop Res 2008 Dec;26(12):1643e8.
8. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immu-
nophenotyping for the human immunology project. Nat Rev
Immunol 2012;12:191e200.
9. Sokolove Jeremy, Lepus Christin M. Role of inﬂammation in the
pathogenesis of osteoarthritis: latest ﬁndings and in-
terpretations. Ther Adv Musculoskelet Dis 2013;5(2):77e94.
10. Walsh DA, Bonnet CS, Turner EL, Wilson D, Situ M,
McWilliams DF. Angiogenesis in the synovium and at the
osteochondral junction in osteoarthritis. Osteoarthritis Carti-
lage 2007;15:743e51.
11. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB,
Bresnihan B. Synovial tissue inﬂammation in early and late
osteoarthritis. Ann Rheum Dis 2005;64:1263e7.
12. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase
and proinﬂammatory cytokine production by chondrocytes of
human osteoarthritic cartilage: associations with degenerative
changes. Arthritis Rheum 2001;44:585e94.13. Lefebvre V, Peeters-Joris C, Vaes G. Modulation by interleukin
1 and tumor necrosis factor a of production of collagenase,
tissue inhibitor of metalloproteinases and collagen types in
differentiated and dedifferentiated articular chondrocytes.
Biochim Biophys Acta 1990;1052:366e78.
14. Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-Pelletier J.
The new collagenase, collagenase-3, is expressed and synthe-
sized by human chondrocytes but not by synoviocytes. A role
in osteoarthritis. J Clin Invest 1996;97:2011e9.
15. Fan Z, Bau B, Yang H, Soeder S, Aigner T. Freshly isolated
osteoarthritic chondrocytes are catabolically more active than
normal chondrocytes, but less responsive to catabolic stimu-
lation with interleukin-1ß. Arthritis Rheum 2005;52:136e43.
16. Bondeson J, Lauder S, Wainwright S, Amos N, Evans A,
Hughes C, et al. Adenoviral gene transfer of the endogenous
inhibitor IkappaBalpha into human osteoarthritis synovial ﬁ-
broblasts demonstrates that several matrix metalloproteinases
and aggrecanases are nuclear factor-kappaB-dependent.
J Rheumatol 2007;34:523e33.
17. Goldring MB, Birkhead J, Sandell LJ, Kimura T, Krane SM.
Interleukin 1 suppresses expression of cartilage-speciﬁc types
II and IX collagens and increases types I and III collagens in
human chondrocytes. J Clin Invest 1988;82:2026e37.
18. Chadjichristos C, Ghayor C, Kypriotou M, Martin G, Renard E,
Ala-Kokko L, et al. Sp1 and Sp3 transcription factors mediate
interleukin-1b down-regulation of human type II collagen
gene expression in articular chondrocytes. J Biol Chem
2003;278:39762e72.
19. Nietfeld JJ, Wilbrink B, Den Otter W, Huber J, Huber-Bruning O.
The effect of human interleukin 1 on proteoglycan metabolism
in human and porcine cartilage explants. J Rheumatol
1990;17:818e26.
20. St€ove J, Huch K, Günther KP, Scharf HP. Interleukin-1b induces
different gene expression of stromelysin, aggrecan and tumor-
necrosis-factor-stimulated gene 6 in human osteoarthritic
chondrocytes in vitro. Pathobiology 2000;68:144e9.
21. Smith MD, Triantaﬁllou S, Parker A, Youssef PP, Coleman M.
Synovial membrane inﬂammation and cytokine production in
patients with early osteoarthritis. J Rheumatol 1997;24:
365e71.
22. Lindblad S, Hedfors E. Arthroscopic and immunohistologic
characterization of knee joint synovitis in osteoarthritis.
Arthritis Rheum 1987;30:1081e8.
23. Haraoui B, Pelletier JP, Cloutier JM, Faure MP, Martel-Pelletier J.
Synovial membrane histology and immunopathology in
rheumatoid arthritis and osteoarthritis: in vivo effects of
antirheumatic drugs. Arthritis Rheum 1991;34:153e63.
24. Ishii H, Tanaka H, Katoh K, Nakamura H, Nagashima M,
Yoshino S. Characterization of inﬁltrating T cells and Th1/Th2-
type cytokines in the synovium of patients with osteoarthritis.
Osteoarthritis Cartilage 2002;10:277e81.
25. Sakkas LI, Scanzello C, Johanson N, Burkholder J, Mitra A,
Salgame P, et al. T cells and T-cell cytokine transcripts in the
synovial membrane in patients with osteoarthritis. Clin Diagn
Lab Immunol 1988;5:430e7.
26. Sakkas Lazaros I, Platsoucas Chris D. The role of T cells in the
pathogenesis of osteoarthritis. Arthritis Rheum Febbruary
2007;56(2):409e24.
27. Saito I, Koshino T, Nakashima K, Uesugi M, Saito T. Increased
cellular inﬁltrate in inﬂammatory synovia of osteoarthritic
knees. Osteoarthritis Cartilage 2002;10:156e62.
28. Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M,
Studnicka-Benke A, Gal A, et al. Cytokine production by
synovial T cells in rheumatoid arthritis. Rheumatology
1999;38:202e13.
A. Lùrati et al. / Osteoarthritis and Cartilage 23 (2015) 88e93 9329. De Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJ,
Zuurmond AM, Schoones J, Toes RE, et al. Synovial inﬂamma-
tion, immune cells and their cytokines in osteoarthritis: a re-
view. Osteoarthritis and Cartilage 2012;20:1484e99.
30. Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines
in rheumatoid arthritis. Best Pract Res Clin Rheumatol
2001;15:677e91.31. Harrington LE, Mangan PR, Weaver CT. Expanding the effector
CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol
2006;18:349e56.
32. Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T.
Reduced expression of the regulatory CD4þ T cell subset is
related to Th1/Th2 balance and disease severity in rheumatoid
arthritis. Arthritis Rheum 2000;43:617e27.
